Table 1.

Patient characteristics for subjects with immune response assessed by 7-plex immunohistochemistry and multispectral imaging and the remaining subjects in the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer substudy

Parameter	Total (N=336)	Immune response assessed (n=66)	Immune response not assessed (n=270)	P value
Age (years), median (IQR)	50 (43–61)	49 (42–58)	51 (43–61)	0.396
Age group (years), n (%)
<40	59	12 (18.2)	47 (17.4)
40–50	94	21 (31.8)	73 (27.0)
50–60	90	18 (27.3)	72 (26.7)
>60	92	14 (21.2)	78 (28.9)
Missing	1	1 (1.5)	0 (0)
Menopausal status, n (%)
Premenopausal	163	36 (54.5)	127 (47.0)	0.187
Postmenopausal	157	25 (37.9)	132 (48.9)
Missing	16	5 (7.6)	11 (4.1)
Histological subtype, n (%)
No special type, ductal	304	60 (90.9)	244 (90.4)	0.999
Invasive lobular	7	1 (1.5)	6 (2.2)
Medullary	9	2 (3.0)	7 (2.6)
Other	12	2 (3.0)	10 (3.7)
Missing	4	1 (1.5)	3 (1.1)
PAM50 subtype, n (%)
Basal	250	57 (86.4)	193 (71.5)	0.487
HER2	19	2 (3.0)	17 (6.3)
LumA	5	0 (0)	5 (1.9)
Normal	26	6 (9.1)	20 (7.4)
Missing	36	1 (1.5)	35 (13.0)
Clinical tumor stage, n (%)
1	125	20 (30.3)	105 (38.9)	0.353
2	188	43 (65.2)	145 (53.7)
3	18	2 (3.0)	16 (5.9)
4	5	1 (1.5)	4 (1.5)
Clinical nodal status, n (%)
0	248	51 (77.3)	197 (73.0)	0.854
1	77	13 (19.7)	64 (23.7)
2–3	11	2 (3.0)	9 (3.3)
Treatment, n (%)
nab-paclitaxel+gemcitabine	182	40 (60.6)	142 (52.6)	0.242
nab-paclitaxel+carboplatin	154	26 (39.4)	128 (47.4)
pCR, n (%)
No	206	42 (63.6)	164 (60.7)	0.992
Yes	118	24 (36.4)	94 (34.8)
Missing	12	0 (0)	12 (4.4)
Ki-67, median (IQR)	72.5 (50–80)	75 (60–90)	70 (50–80)	0.152
Missing	12	0	12
Early response, n (%)
No	118	37 (56.9)	81 (41.1)	0.026*
Yes	144	28 (43.1)	116 (58.9)
Missing	74	1 (1.5)	73 (27.0)

*Among patients with evaluable pCR.

pCR, pathological complete response.